VivoSeq
Other

Memory Impairment

19

Pipeline Programs↗

0

Active Trials↗

11

Companies Involved↗

Memory Impairment is an emerging landscape with 19 programs across 11 companies. The most active players are Novartis, Lexicon Pharmaceuticals, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 11 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

0/100

Mech. Concentration

14/100

Completion Rate

91/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2L

Lexicon Pharmaceuticals

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

2 programs

ApprovedEisai logo

Eisai

1 program

ApprovedAmgen logo

Amgen

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

13

clinical trials

Completed10 · 77%
Unknown status2 · 15%
Terminated1 · 8%

Clinical Trials

Trial Activity

13 trials

Attention & Memory Impairments in Menopausal Women
Completed·UUniversity of Pennsylvania·Phase 4·NCT01324024·35 enrolled
Combination Treatment Study for Memory Impairment and Depression
Completed·NNew York State Psychiatric Institute·Phase 4·NCT01658228·86 enrolled
Vilazodone for Corticosteroid-Induced Memory Impairment
Completed·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT01828515·24 enrolled
Tricaprilin In Age-Associated Memory Impairment
Completed·CCerecin·Phase 2·NCT00355550·156 enrolled
HT-0712 vs. Placebo in Subjects With Age-Associated Memory Impairment (AAMI)
Completed·DDart NeuroScience, LLC·Phase 2·NCT02013310·119 enrolled
Phenytoin for Memory Impairment Secondary to Megestrol
Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT02595723·21 enrolled
Reversing Corticosteroid Induced Memory Impairment
Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT01142310·54 enrolled
Anti-Inflammatory Treatment for Age-Associated Memory Impairment: A Double-Blind Placebo-Controlled Trial
Completed·UUniversity of California, Los Angeles·Phase 3·NCT00009230
Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment
Completed·LLexicon Pharmaceuticals·Phase 2·NCT00691808·103 enrolled
A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)
Completed·TTargacept Inc.·Phase 2·NCT00109564·174 enrolled
Effect of AQW051 in Patients With Memory Impairment
Terminated·Novartis logoNovartis·Phase 2·NCT00582855·54 enrolled
Efficacy of Pharmacological Treatment of Working Memory Impairment After Traumatic Brain Injury: Evaluation With fMRI
Unknown status·KKessler Foundation·N/A·NCT00489892·20 enrolled
Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease
Unknown status·PPeking University Third Hospital·Phase 4·NCT04968613·150 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)